SCHEMBL415199

SCHEMBL415199

CCNCC1(C(=O)c2cc3ccccc3s2)CCNC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.69
SLC6A2 P23975 4/20 0.69
SLC6A4 P31645 4/20 0.69
SLC6A3 Q01959 4/20 0.69
RAB9A P51151 1/20 0.45
HDAC3 O15379 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
BCL2L1 Q07817 1/20 0.40
OPRM1 P35372 3/20 0.38
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12350681 0.87 CYP2D6 (0.54) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL413046 0.85 SLC6A2 (0.80) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL415124 0.85 SLC6A2 (0.80) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL414142 0.85 SLC6A2 (0.80) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL413700 0.82 SLC6A2 (0.71) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL415336 0.81 CYP2D6 (1.00) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL413722 0.81 CYP2D6 (1.00) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL413712 0.81 CYP2D6 (1.00) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL413137 0.81 CYP2D6 (0.69) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL442481 0.80 CYP2D6 (0.59) CYP2D6SLC6A2SLC6A4SLC6A3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065225-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF IYER PRAVIN (US) 2012-03-15 US disclosed
US-20120065225-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF IYER PRAVIN (US) 2012-03-15 US disclosed
US-8084623-B2 heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents ROCHE PALO ALTO LLC (US) 2011-12-27 US disclosed
US-8084623-B2 heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents ROCHE PALO ALTO LLC (US) 2011-12-27 US disclosed
EP-2102157-B1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-22 EP disclosed
WO-2008074703-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065225-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF CNKSR1, RB1, AR CYP2D6 227/4885SLC6A2 4870/4885SLC6A4 4855/4885
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof CNKSR1, RB1, AR CYP2D6 227/4885SLC6A2 4870/4885SLC6A4 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.